NASDAQ · GLMD
Healthcare · Biotechnology
$3.92
Down-$0.04 (-1.02%)
Updated Sep 4, 2026, 10:37 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
GLMD closed at $3.92 after 21 trading sessions, up 554.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $4.05 | $4.062 | $3.90 | $3.92 | 12.13K |
| Sep 2, 2026 | $3.97 | $4.223 | $3.94 | $4.119 | 15.62K |
| Sep 1, 2026 | $4.07 | $4.12 | $3.8176 | $3.925 | 24.18K |
| Aug 31, 2026 | $4.04 | $4.16 | $4.03 | $4.12 | 7.21K |
| Aug 28, 2026 | $4.16 | $4.26 | $3.9588 | $4.165 | 5.37K |
| Aug 27, 2026 | $4.29 | $4.38 | $4.16 | $4.3056 | 6.12K |
| Aug 26, 2026 | $4.28 | $4.40 | $4.22 | $4.33 | 4.58K |
| Aug 25, 2026 | $4.08 | $4.49 | $3.9601 | $4.3053 | 40.19K |
| Aug 24, 2026 | $4.11 | $4.1298 | $3.6792 | $4.05 | 48.29K |
| Aug 21, 2026 | $4.54 | $4.54 | $4.12 | $4.305 | 22.21K |
| Aug 20, 2026 | $4.56 | $4.80 | $4.22 | $4.56 | 107.78K |
| Aug 19, 2026 | $5.38 | $5.4501 | $4.10 | $4.77 | 231.14K |
| Aug 18, 2026 | $4.208 | $4.624 | $4.16 | $4.4816 | 36.91K |
| Aug 17, 2026 | $4.16 | $4.88 | $3.9992 | $4.1072 | 120.95K |
| Aug 14, 2026 | $4.156 | $4.248 | $4.08 | $4.1848 | 5.69K |
| Aug 13, 2026 | $4.328 | $4.5464 | $4.24 | $4.248 | 3.64K |
| Aug 12, 2026 | $0.5569 | $0.5816 | $0.53 | $0.56 | 117.09K |
| Aug 11, 2026 | $0.5701 | $0.575 | $0.5501 | $0.5569 | 29.52K |
| Aug 10, 2026 | $0.598 | $0.60 | $0.5805 | $0.5931 | 14.65K |
| Aug 7, 2026 | $0.5741 | $0.6019 | $0.5729 | $0.6019 | 21.98K |
| Aug 6, 2026 | $0.5696 | $0.60 | $0.56 | $0.599 | 13.47K |
The latest Smart Investors Daily articles mentioning GLMD.
GLMD research
Company profile and research snapshot.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 4, 2025 | Maxim Group | Hold | — |
| Jul 24, 2023 | Maxim Group | Buy | — |
| Aug 8, 2022 | Maxim Group | Hold | — |
| Aug 8, 2022 | Canaccord Genuity | Hold | — |
| May 18, 2022 | Raymond James | Market Perform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode Therapeutics
Benzinga · Aug 19, 2026
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of
Benzinga · Aug 17, 2026
Xtandi (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer
Benzinga · Jul 28, 2026
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration.In order to improve patient convenience and long-term treatment adherence by
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLMD.
